Related Experiment Video
Updated: Jan 6, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Bidirectional Causal Associations Between Plasma Metabolites and Parkinson's Disease
Mengjie Zhao1, Taiping Li2, Hong Shen2
1Department of Neuro-Psychiatric Institute, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, 210029, China. nbhzmj@njmu.edu.cn.
None:
In plasma samples of patients with neuropsychitraic disorders, the levels of many metabolites differ from those in healthy controls. Causal connections between Parkinson's disease (PD), one of the most prevalent degenerative disorders, and the levels of plasma metabolites remain unclear. Bidirectional metabolome-wide Mendelian randomization (MR) analysis was performed to explore the potential causative associations between PD in a genome-wide association study (GWAS) dataset with 5,150 cases and 448,583 controls, and the levels of 871 plasma circulating metabolites (N = 8,299). The MR analysis detected 38 metabolites associated with PD. Fourteen of these metabolites were associated with a reduced risk of PD (odds ratio (OR): 0.86-0.92), along with 24 metabolites contributing to elevated risks of PD (OR: 1.06-1.23). In reverse MR analysis, genetic signature of PD had positive causal effects on the levels of 35 circulating metabolites (OR: 1.04-1.07) and negative causal effects on the levels of 13 metabolites (OR: 0.94-0.96). For three circulating metabolites levels, including behenoyl dihydrosphingomyelin (d18:0/22:0), 1-stearoyl-GPE (18:0) as well as N-palmitoyl-sphingadienine (d18:2/16:0), bi-directional causative relationships with PD were uncovered. Our findings revealed a network of bidirectional causal associations between the levels of individual plasma metabolites and the risks of PD, providing possible clues for the prevention and the therapy of this disorder.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease: Overview
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Neural Regulation
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

